https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / Nippon Rinsho 2005 Sep;63 Suppl 9:483-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / Nippon Rinsho 2005 Sep;63 Suppl 9:483-92005-09-01 00:00:002019-02-15 09:00:05[Current status of hyperthermia for therapy of brain tumor]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / Hepatogastroenterology 2005 Sep-Oct;52(65):1502-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / Hepatogastroenterology 2005 Sep-Oct;52(65):1502-62005-09-01 00:00:002019-02-15 09:03:11Immune-related effects of local hyperthermia in patients with primary liver cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):505-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):505-162005-09-01 00:00:002019-02-15 09:19:57Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / Aktuelle Urol 2005 Sep;36(5):407-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / Aktuelle Urol 2005 Sep;36(5):407-162005-09-01 00:00:002019-02-15 09:24:21[Vaccine therapy of prostate cancer]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):461-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):461-62005-09-01 00:00:002019-02-15 09:25:43B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):496-504
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):496-5042005-09-01 00:00:002020-01-08 10:10:20Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-08-23 / Blood 2005 Dec;106(13):4225-33
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-08-23 / Blood 2005 Dec;106(13):4225-332005-08-23 00:00:002019-02-15 08:44:44Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-08-18 / Vaccine 2005 Nov;23(45):5225-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-08-18 / Vaccine 2005 Nov;23(45):5225-302005-08-18 00:00:002005-08-18 00:00:00Antitumor activity of a fusion of esophageal carcinoma cells with dendritic cells derived from cord blood
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-08-15 / Cancer 2005 Aug;104(4):763-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-08-15 / Cancer 2005 Aug;104(4):763-702005-08-15 00:00:002019-02-15 08:35:31First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-08-01 / Oncol. Rep. 2005 Aug;14(2):353-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-08-01 / Oncol. Rep. 2005 Aug;14(2):353-62005-08-01 00:00:002019-02-15 08:36:23Prognostic significance of CD83 positive, mature dendritic cells in the gallbladder carcinoma
